CR10342A - INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3 - Google Patents

INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3

Info

Publication number
CR10342A
CR10342A CR10342A CR10342A CR10342A CR 10342 A CR10342 A CR 10342A CR 10342 A CR10342 A CR 10342A CR 10342 A CR10342 A CR 10342A CR 10342 A CR10342 A CR 10342A
Authority
CR
Costa Rica
Prior art keywords
task
respiratory disorders
inhibitors
ias
channels
Prior art date
Application number
CR10342A
Other languages
English (en)
Inventor
Joachim Brendel
Heinz Goegelein
Klaus Wirth
Walter Kamm
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006019589A external-priority patent/DE102006019589A1/de
Priority claimed from DE102006049527A external-priority patent/DE102006049527A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR10342A publication Critical patent/CR10342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere al uso de inhibidores de Kv1.5 para producir un medicamento para la terapia o profilaxis de trastornos respiratorios relacionados con el sueno, apneas del sueno central y obstructivas, sindrome de la resistencia de vias aereas superiores, respiracion de Cheyne-Stokes, ronquido, impulso respiratorio central interrumpido, muerte infantil subita, hipoxia y apnea post-operativas, trastornos respiratorios relacionados con la musculatura, trastornos respiratorios tras ventilacion a largo plazo, trastornos respiratorios durante adaptacion a la alta montana.
CR10342A 2006-04-27 2008-10-06 INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3 CR10342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006019589A DE102006019589A1 (de) 2006-04-27 2006-04-27 Inhibitoren des TASK-1 und Task-3 Ionenkanals
DE102006049527A DE102006049527A1 (de) 2006-10-20 2006-10-20 Inhibitoren des TASK-1 und TASK-3 Ionenkanals

Publications (1)

Publication Number Publication Date
CR10342A true CR10342A (es) 2009-01-09

Family

ID=38258824

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10342A CR10342A (es) 2006-04-27 2008-10-06 INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3

Country Status (26)

Country Link
US (1) US20090149496A1 (es)
EP (1) EP2012758A2 (es)
JP (1) JP5161871B2 (es)
KR (1) KR101390239B1 (es)
CN (1) CN101636154B (es)
AR (1) AR060822A1 (es)
AU (1) AU2007245891B2 (es)
BR (1) BRPI0710946A2 (es)
CA (1) CA2650391C (es)
CO (1) CO6140023A2 (es)
CR (1) CR10342A (es)
DO (1) DOP2007000083A (es)
EC (1) ECSP088847A (es)
GT (1) GT200800213A (es)
IL (1) IL194868A (es)
MA (1) MA30357B1 (es)
MX (1) MX2008012920A (es)
NO (1) NO20084513L (es)
NZ (1) NZ572231A (es)
PE (1) PE20080061A1 (es)
RU (1) RU2436577C2 (es)
SG (1) SG163543A1 (es)
TN (1) TNSN08431A1 (es)
TW (1) TWI398432B (es)
UY (1) UY30313A1 (es)
WO (1) WO2007124849A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012712A (es) 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
BRPI1011098A2 (pt) * 2009-06-03 2016-04-12 Sanofi Aventis Deutschland fases cristalinas de (2-piridin-3-il-etil)-amida de ácido 2'-{[2-(4-metóxi-fenil)-acetilamino]metil}-bifenil-2-carboxílico.
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
WO2011103715A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2013037736A1 (en) 2011-09-12 2013-03-21 Sanofi Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
JP5893143B2 (ja) * 2011-09-12 2016-03-23 サノフイ インダニル置換の４，５，６，７−テトラヒドロ−１Ｈ−ピラゾロ［４，３−ｃ］ピリジン、医薬としてのその使用、及びそれらを含む医薬製剤
WO2013037914A1 (en) 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
EP2755973B1 (en) 2011-09-16 2015-11-04 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
ES2623167T3 (es) 2012-02-03 2017-07-10 Sanofi Pirroldicarboxamidas condensadas y su uso como productos farmacéuticos
CN104721832A (zh) * 2013-12-18 2015-06-24 深圳先进技术研究院 携带编码光敏感离子通道蛋白基因的表达载体在制备调控呼吸节律药物中的应用
AU2016232749B2 (en) * 2015-03-18 2021-09-23 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
JOP20190005A1 (ar) * 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CA3043325A1 (en) 2016-11-10 2018-05-17 The Research Foundation For The State University Of New York System, method and biomarkers for airway obstruction
WO2018119126A1 (en) * 2016-12-20 2018-06-28 The University Of Chicago L-pag derivatives for treatment of sleep disordered breathing (sdb)
JOP20190148A1 (ar) * 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) * 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
EP3338803A1 (de) * 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
EP3338764A1 (de) * 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
GEP20247606B (en) * 2018-11-27 2024-03-11 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CN119462558B (zh) * 2024-10-18 2025-09-19 河南中医药大学 一种布美他尼衍生物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
DE19929076A1 (de) * 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6716879B2 (en) * 2000-08-30 2004-04-06 Compass Pharmaceuticals, Llc Methods for anti-tumor therapy
GB2372503A (en) * 2000-10-19 2002-08-28 Glaxo Group Ltd Voltage-gated potassium channel polypeptides
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
AU2004276267B2 (en) * 2003-09-23 2010-08-19 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US20080125432A1 (en) * 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
CN101636154B (zh) 2011-12-14
IL194868A (en) 2014-01-30
US20090149496A1 (en) 2009-06-11
GT200800213A (es) 2009-05-04
RU2436577C2 (ru) 2011-12-20
CN101636154A (zh) 2010-01-27
TNSN08431A1 (en) 2010-04-14
SG163543A1 (en) 2010-08-30
RU2008146755A (ru) 2010-06-10
CA2650391C (en) 2015-12-15
JP5161871B2 (ja) 2013-03-13
HK1138183A1 (en) 2010-08-20
EP2012758A2 (en) 2009-01-14
TW200808708A (en) 2008-02-16
JP2009534434A (ja) 2009-09-24
KR101390239B1 (ko) 2014-04-30
AU2007245891B2 (en) 2012-10-18
AR060822A1 (es) 2008-07-16
MX2008012920A (es) 2008-10-15
NZ572231A (en) 2010-12-24
MA30357B1 (fr) 2009-04-01
WO2007124849A3 (en) 2009-10-08
UY30313A1 (es) 2007-11-30
PE20080061A1 (es) 2008-03-24
WO2007124849A2 (en) 2007-11-08
ECSP088847A (es) 2008-11-27
AU2007245891A1 (en) 2007-11-08
CA2650391A1 (en) 2007-11-08
DOP2007000083A (es) 2007-11-15
CO6140023A2 (es) 2010-03-19
TWI398432B (zh) 2013-06-11
IL194868A0 (en) 2009-08-03
KR20080111509A (ko) 2008-12-23
NO20084513L (no) 2008-11-24
BRPI0710946A2 (pt) 2012-03-06

Similar Documents

Publication Publication Date Title
CR10342A (es) INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3
PH12019502427A1 (en) Methods and compositions for treating sleep apnea
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
MX2025004365A (es) Metodos y composiciones para el tratamiento de la apnea del sue?o
JOP20210059A1 (ar) مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم
PH12021551186A1 (en) Process for producing pharmaceutical dosage forms comprising inhibitors of task-1 and task-3 channels and use thereof for therapy of respiratory disorders
DK1715859T3 (da) Fremgangsmåde til behandling og diagnosticering af åndedrætsforstyrrelser i sövnen ved hjælp af zonisamid og midler til at gennemföre fremgangsmåden
MX2009003676A (es) Compuestos s-nitrosotiol y derivados relacionados.
MX2009010805A (es) Metodos y composiciones que comprenden desvenlafaxina o duloxetina para el tratamiento de trastornos de la respiracion relacionados con el sueño.
MX2024007768A (es) Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
WO2007047575A3 (en) Pharmacological treatments for sleep-related breathing disorders
UA98460C2 (ru) Применение ингибиторов ионных task-1 i task-3 каналов
MX2024008522A (es) Derivados de 2,3-dihidrobenzo[b][1,4]dioxin-2-ilmetil)piperazin-1- ilo para el tratamiento de la apnea del sue?o.
MX2021005842A (es) Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño.
Ryan et al. Effect of a Nasal Pillow on Compliance, Nasal Symptoms and Quality of Life in Patients with Obstructive Sleep Apnea Syndrome Using Continuous Positive Airway Pressure Therapy.
CN103690297A (zh) 防止睡眠打呼噜腰封
AU2006904770A0 (en) Automatic Positive Airway Pressure Therapy through the nose or mouth for treatment of Sleep Apnea and other respiratory disorders
UA35599U (ru) Способ коррекции сурфактантных свойств крови у больных хроническим обструктивным заболеванием легких на фоне гипертонической болезни